XL092 for Radioiodine Refractory Differentiated Thyroid Cancer
This study is testing a medication called XL092 for people with differentiated thyroid cancer that has not responded to previous radioiodine treatment and has spread locally or to other parts of the body (metastatic). XL092 is a type of drug called a tyrosine kinase inhibitor, which works by blocking signals that help cancer cells grow. The study aims to see how well XL092 prevents the cancer from getting worse (progression-free survival) and how safe it is. To join, you must have this specific type of thyroid cancer that has progressed within the last 12 months. The study is currently recruiting a planned 33 participants, but its overall status is unclear.
- Study design
- This is an interventional study with a planned enrollment of 33 participants. It is a Phase II trial, meaning it's testing how well the treatment works and its safety.
- What's involved
- You would take XL092 by mouth daily for 21 days in each 21-day cycle. You would also have CT scans, MRI scans, X-rays, and provide blood and urine samples throughout the study.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your progression-free survival will be assessed for up to 12 months from the first dose of XL092.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer
At a glance
Conditions
Where it's being run
2 sites across 2 statesStudy leadership
- Jochen H Lorch · PRINCIPAL_INVESTIGATOR · Northwestern University
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Progression free survival (PFS)From the time of the first dose of XL092 to the first documentation of disease progression, initiation of subsequent anti-cancer therapy, completion of 12 months of participation, or death from any cause, whichever occurs first, assessed at 12 months
Progression is defined according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1 criteria. Median PFS at 12-months will be analyzed using the Kaplan-Meier method. The 12-month PFS estimate will be reported along with the confidence interval. Cox proportional hazards models will be applied to assess the impact of covariates such as age, sex, baseline disease severity, and genetic markers on PFS, when appropriate.